title: [Analysis of efficacy and safety of administration of moxonidine in patients with arterial hypertension and hypertensive crises].
abstract: In the review we present detailed analysis of antihypertensive action of 3-nd generation sympatholytic moxonidine. Due to selective interaction with imidazoline I1-receptors moxonidine diminishes sympathetic activity causing lowering of peripheral vascular resistance. This leads to significant lowering of systolic and diastolic arterial pressure. Efficacy and safety of the drug has been shown both for the management of uncomplicated hypertensive crises and long term treatment of arterial hypertension (AH). Appropriateness of the use of moxonidine in patients with AH combined with diabetes mellitus, metabolic syndrome, chronic obstructive pulmonary disease has been confirmed. Moxonidine is well tolerated; its bioavailability after oral intake reaches 90%. The drug produces neither hypotensive "first dose" nor rebound effects.
authors: N I
authors: NI
authors: Gaponova
authors: V R
authors: VR
authors: Abdrakhmanov
authors: V L
authors: VL
authors: Baratashvili
authors: S N
authors: SN
authors: Tereshchenko
mesh_terms: D000284:Administration, Oral; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects; D001682:Biological Availability; D001794:Blood Pressure / Q000187:drug effects*; D006801:Humans; D006974:Hypertension, Malignant / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D054755:Imidazoline Receptors / Q000378:metabolism*; D012720:Severity of Illness Index; D013564:Sympathetic Nervous System / Q000187:drug effects*; D016896:Treatment Outcome; D014655:Vascular Resistance / Q000187:drug effects*
chemical_list: D000959:Antihypertensive Agents; D007093:Imidazoles; D054755:Imidazoline Receptors; C043482:moxonidine